PlasmaGen Biosciences raises Rs 150 crore in round

PlasmaGen Biosciences, a biopharmaceutical company focused on blood plasma-derived therapeutics, Rs 150 crore in a minority equity financing round led by ViNS Bioproducts.

The round also saw participation from high-net-worth individuals (HNIs), family offices, pharma entrepreneurs, and existing investors. 

The Bengaluru-based startup, backed by Eight Road Ventures, raised funds at a valuation of over ₹1,500 crore.

The new funds will be used to grow international operations, expand the product range, and strengthen the company’s team and systems.

Read also- Best Leading Chai Startups in India for 2026

“The past year has been transformational for PlasmaGen, marking a step change in the scale and reach of the company. This momentum has put us on an exponential growth trajectory,” said Vivek V Kamath, chief executive officer of PlasmaGen Biosciences.

“With a clear plan and the support of this financing, we are well positioned to turn our ambition into enduring impact for patients and partners worldwide,” he added.

“From the outset, our objective has been to create a worldclass, India-based plasma biopharmaceutical platform that delivers consistent quality and meaningful patient impact,” said, Vinod Nahar, founder and executive chairman of PlasmaGen Biosciences.

Advertisment

“This investment further strengthens PlasmaGen’s position as a long-term partner to healthcare systems and patients, both in India and internationally,” he added.

Established in 2010, PlasmaGen Biosciences makes and sells plasma-based medicines such as Immunoglobulin, Albumin, and clotting factors to help meet India’s shortage of these essential drugs. It runs a modern plasma fractionation plant in Kolar, Karnataka, and supplies treatments used in neurology, blood disorders and critical care. The company aims to help India become selfreliant in plasma products.

PlasmaGen has identified distribution partners in major international markets and is working on getting regulatory approvals to start selling abroad. India remains its main focus, and the company is expanding its reach to hospitals and doctors through a cold-chain-supported distribution network.

The company began commercial operations in 2024 at its Kolar facility near Bengaluru. PlasmaGen says this plant is one of only five such facilities in India and claims it is the country’s first pure-play plasma biopharma company. It has seen strong revenue growth since starting operations and is now preparing to expand into global markets.

Want to go deeper into the world of startups and entrepreneurship? Check out these categories on VIESTORIES:

Latest Business and Startup News: Discover Funding Trends and Stories Shaping Indian Startups.

Advertisment

Startup Funding News: Your Gateway to Every Funding Update.

Latest Startup News: Stay updated with the latest startup news and trends. Your go-to source for startup ecosystem updates.

Startup Stories: Discover inspiring tales of startups overcoming challenges, and achieving success.